A familial case of Birt–Hogg–Dubé syndrome complicated with various cancers

Yuki Goto, Kazunori Tobino, Miyuki Munechika, Yuki Yoshimatsu, Hiromi Ide & Kosuke Tsuruno
Respiratory Medicine, Iizuka Hospital, Iizuka, Japan.

Keywords
Birt–Hogg–Dubé syndrome, bladder cancer, lung cancer, pneumothorax, renal cancer.

Correspondence
Yuki Goto, Respiratory Medicine, Iizuka Hospital, 3-83 Yoshiomachi, Iizuka, Fukuoka 820-0018, Japan. E-mail: ygotoh3@aih-net.com

Received: 30 December 2019; Revised: 12 February 2020; Accepted: 25 February 2020; Associate Editor: Coenraad Koegelenberg.

Respirology Case Reports, 8 (4), 2020, e00549
doi: 10.1002/rcr2.549

Abstract
An 89-year-old woman with small papules on her face presented to our hospital complaining of progressive dyspnoea. Chest computed tomography (CT) showed bilateral multiple lung cysts, a nodular opacity in the right lower lobe, and bilateral pleural effusion. She was diagnosed with adenocarcinoma. Her son, a 65-year-old man, also had bilateral basally located lung cysts and a past medical history of spontaneous pneumothorax. He had multiple papules on the face and neck, which were pathologically diagnosed as fibrofolliculomas. We considered these cases to be Birt–Hogg–Dubé syndrome (BHDS). Follliculin (FLCN) gene mutations that may be tumour suppressive are suspected to be causative of this syndrome. FLCN dysfunction might lead to the development of various types of tumours other than renal tumours.

Introduction
Birt–Hogg–Dubé syndrome (BHDS) is a rare autosomal dominant inherited disorder characterized by fibrofolliculomas, renal tumours, lung cysts, and pneumothorax [1]. BHDS is caused by germline mutations in the folliculin (FLCN) gene, which encodes the folliculin tumour-suppressor protein. It was reported that patients with this disease have a sevenfold higher risk of developing renal tumours [2]; however, other various neoplasms have been described in patients with BHDS. We herein report a familial case of BHDS complicated with various cancers.

Case Report
An 89-year-old woman was referred to our hospital complaining of progressive dyspnoea. She had a past medical history of bronchial asthma, gastric cancer, and bladder cancer. She had no history of smoking or exposure to any toxic materials. Her oxygen saturation on room air was 94% and her other vital signs were normal. On physical examination, small papules on and around her nose and cheeks were noted. Chest computed tomography (CT) scan demonstrated multiple cysts in both lungs (Fig. 1), which were predominantly located in the basilar medial regions of the lung. It also demonstrated a mass in the right lower lobe, bilateral pleural effusion, and pericardial effusion (Fig. 1). She underwent transbronchial tumour biopsy and a pathological examination revealed lung adenocarcinoma.

At the same time, her son, a 65-year-old man was referred to our department for pneumothorax. He had a past medical history of recurrent spontaneous pneumothorax, ureter cancer, and bladder cancer. He also had a 90 pack-year smoking history. A physical examination revealed multiple papules on his face and neck. Chest CT demonstrated left-sided pneumothorax and bilateral basally located multiple lung cysts (Fig. 2). He underwent punch skin biopsy and a pathological examination revealed fibrofolliculomas (Fig. 2). Although we did not perform genetic analysis, the patient met the diagnostic criteria for BHDS proposed by the BHD consortium: one major criterion, “at least five fibrofolliculomas or trichodiscomas, at least one histologically confirmed, of adult onset,” and one minor criterion, “multiple lung cysts: bilateral basally located lung cysts with no other apparent cause, with or without spontaneous primary pneumothorax” [1]. His mother met two minor criteria (i.e. “typical lung cysts” and “a first-degree relative with BHDS”) and was also diagnosed with BHDS.
The female patient decided not to receive anti-tumour treatment because of her older age and low Eastern Cooperative Oncology Group Performance Status (3–4), and palliative care was started. She died of lung cancer at one and a half months after her admission. Her son's pneumothorax improved without treatment. Since then, he has been regularly monitored for recurrence of pneumothorax and urological tumours.

Discussion

BHDS was first reported in 1977 and is an autosomal dominant inherited disorder caused by a germline mutation coding for FLCN mapped to chromosome 17p11.2, which encodes a highly conserved tumour-suppressor protein. FLCN mRNA is expressed in various tissues, including the skin and its appendages, the distal nephron of the kidney, stromal cells and type 1 pneumocytes of the lung, epithelial ducts of the breast, acinar cells of the pancreas, serous parotid glands, and ovaries [3]. Since FLCN gene was first reported in 2001, over 140 FLCN gene mutations have been reported. The most frequent of these is a hot spot mutation within a polycytosine C8 tract of exon 11; this has been found in the germline of 44% of BHDS patients [4]. Its dysfunction might lead to the development of some types of tumours, including renal cancer. To date, several other tumour types have been reported in association with BHDS, including colon polyps and tumours, breast cancer, and lung cancer [5]. Their real association with BHDS has not yet been clinically validated and additional studies are needed to address this issue.

With regard to our two patients, the former case (mother) had a past medical history of gastric and bladder cancer, and was diagnosed with primary lung adenocarcinoma at her most recent presentation. To the best of our knowledge, only four cases of lung cancer complicating BHDS have been reported (Table 1) [5–7]. Three out of five reported patients (including our patient) were diagnosed with adenocarcinoma. FLCN mutations (c.1285dupC exon 11) were detected in two patients, whereas genetic analyses were not performed in the other two (including our patient).

On the basis of a functional analysis, it was reported that the FLCN gene may interact with FLCN-interacting protein-1 (FNIP1) and -2 (FNIP2), which induce signal transduction through 5' AMP-activated protein 1 (AMPK) and mammalian target of rapamycin (mTOR), while FNIP1 interacts with AMPK and regulates mTOR activity.

Table 1. Previous reported cases of BHDS with lung malignancies.

| Author          | Age/gender | Smoking history   | Clinical presentation | FLCN gene mutations |
|-----------------|------------|-------------------|-----------------------|---------------------|
| Nishida et al. [5] | 65/F       | Current, 25 pack-year | Adenocarcinoma       | c.1285dupC exon 11  |
| Nishida et al. [5] | 59/F       | Current, 45 pack-year | Adenocarcinoma       | Not determined      |
| Furuya et al. [6] | Not determined/F | Not determined     | Bronchoalveolar carcinoma | c.1285dupC exon 11  |
| Gunji-Niitsu et al. [7] | 38/F       | Ex-smoker, 0.6 pack-year | Clear cell “sugar” tumour | c.1347_1353dupCCACCT exon 12 |
| This case (mother) | 89/F       | Never-smoker       | Adenocarcinoma       | Not determined      |

BHDS, Birt–Hogg–Dubé syndrome; FLCN, folliculin.

© 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology
The FLCN mutation may suppress or activate mTOR, the dysregulation of the mTOR pathway may result in the dysregulation of cell growth and protein synthesis, thereby leading to tumourigenesis [9]. The patient’s son had a past medical history of ureter and bladder cancer, both were histologically diagnosed as urothelial carcinoma. The causal relationship between BHDS and bladder cancer was suspected because the former case (mother) had no specific risk factors of bladder cancer; however, her son had the 90 pack-year smoking history that is one of the risk factors of bladder cancer and little has been reported on the association between BHDS and bladder cancer.

In conclusion, FLCN mutations might be related to tumourigenesis in the lung or urinary organs. It is reported that most cancers developed after the appearance of fibrofolliculomas or pneumothorax. If BHDS can be diagnosed earlier based on these findings, the early detection and treatment of cancer may be possible.

Disclosure Statement
Appropriate written informed consent was obtained for publication of this case report and accompanying images.

References
1. Menko FH, van Steensel MA, Giraud S, et al. 2009. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 10:1199–1206.
2. Zbar B, Alvord WG, Glenn G, et al. 2002. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol. Biomarkers Prev. 11(4):393–400.
3. Warren MB, Torres-Cabala CA, Turner ML, et al. 2004. Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod. Pathol. 17:998–1011.
4. Nickerson ML, Warren MB, Toro JR, et al. 2002. Mutations in a novel gene lead to kidney tumors, lung wall defects, and...
benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2:157–164.

5. Nishida C, Yatera K, Yamasaki K, et al. 2015. Possible familial case of Birt-Hogg-Dubé syndrome complicated with lung cancer: a possible link between these two disease entities. Respir. Med. 109:923–925.

6. Furuya M, and Nakatani Y. 2013. Birt-Hogg-Dube syndrome: clinicopathological features of the lung. J. Clin. Pathol. 66:178–186.

7. Gunji-Niitsu Y, Kumasaka T, Kitamura S, et al. 2016. Benign clear cell "sugar" tumor of the lung in a patient with Birt-Hogg-Dubé syndrome: a case report. BMC Med. Genet. 17:85.

8. Baba M, Hong SB, Sharma N, et al. 2006. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. U.S.A. 103:15552–15557.

9. Baba M, Furihata M, Hong SB, et al. 2008. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyper-proliferation, and polycystic kidneys. J. Natl. Cancer Inst. 100:140–154.